Combined use of two or more prostaglandins or prostaglandin analogs not recommended. Administration more than once daily may decrease IOP lowering effect or cause paradoxical IOP elevations.
Source: NLP:latanoprost ophthalmic solution 0.005%
Brand names: Iyuzeh
Prostaglandin Analog
Route: Ophthalmic
Contraindications
4 CONTRAINDICATIONS Known hypersensitivity to latanoprost or any other ingredients in this product. Known hypersensitivity to latanoprost or any other ingredients in this product. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of IYUZEH administration in pregnant women to inform drug-associated risks. In animal reproduction studies, intravenous (IV) administration of latanoprost to pregnant rabbits and rats throughout the period of organogenesis produced malformations, embryofetal lethality and spontaneous abortion at clinically relevant doses (equivalent to 1.3 – 324 times the maximum recommended human ophthalmic dose, on a mg/m 2 basis, assuming 100% absorption) (see Data ) . The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20% of clinically recognized pregnancies. Data Animal Data Embryofetal studies were conducted in pregnant rabbits administered latanoprost daily by IV injection on gestation days 6 through 18, to target the period of organogenesis. A no observed adverse effect level (NOAEL) was not established for rabbit developmental toxicity. Post-implantation loss due to late resorption was shown as doses ≥0.2 mcg/kg/day (equivalent to 1.3 times the maximum recommended human ophthalmic dose [RHOD], on a mg/m 2 basis, assuming 100% absorption). Spina bifida and abortion occurred at 5 mcg/kg/day (equivalent to 32 times the maximum RHOD). Total litter loss due to early resorption was observed at doses ≥50 mcg/kg/day (324 times the maximum RHOD). Transient signs of maternal toxicity were observed after IV dosing (increased breathing, muscle tremors, slight motor incoordination) at 300 mcg/kg/day (1946 times the maximum RHOD). No maternal toxicity was observed at doses up to 50 mcg/kg/day. Embryofetal studies were conducted in pregnant rats administered latanoprost daily by IV injection on gestation days 6 through 15, to target the period of organogenesis. A NOAEL for rat developmental toxicity was not established. Cleft palate was observe
6 interactions on record
Combined use of two or more prostaglandins or prostaglandin analogs not recommended. Administration more than once daily may decrease IOP lowering effect or cause paradoxical IOP elevations.
Source: NLP:latanoprost ophthalmic solution 0.005%
Combined use of two or more prostaglandins or prostaglandin analogs not recommended. Administration more than once daily may decrease IOP lowering effect or cause paradoxical IOP elevations.
Source: NLP:latanoprost ophthalmic solution 0.005%
Combined use of two or more prostaglandins or prostaglandin analogs not recommended. Administration more than once daily may decrease IOP lowering effect or cause paradoxical IOP elevations.
Source: NLP:latanoprost ophthalmic solution 0.005%
Combined use with other prostaglandins or prostaglandin analogs not recommended. More than once daily administration may decrease IOP lowering effect or cause paradoxical IOP elevations.
Source: NLP:latanoprost ophthalmic solution 0.005%
Combined use of two or more prostaglandins or prostaglandin analogs not recommended. Administration more than once daily may decrease IOP lowering effect or cause paradoxical IOP elevations.
Source: NLP:latanoprost ophthalmic solution 0.005%
Combined use of two or more prostaglandins or prostaglandin analogs not recommended. Administration more than once daily may decrease IOP lowering effect or cause paradoxical IOP elevations.
Source: NLP:latanoprost ophthalmic solution 0.005%